Potential implication of residual viremia in patients on effective antiretroviral therapy.

Abstract

The current antiretroviral therapy (ART) has suppressed viremia to below the limit of detection of clinical viral load assays; however, it cannot eliminate viremia completely in the body even after prolonged treatment. Plasma HIV-1 loads persist at extremely low levels below the clinical detection limit. This low-level viremia (termed "residual viremia") cannot be abolished in most patients, even after the addition of a new class of drug, i.e., viral integrase inhibitor, to the combined antiretroviral regimens. Neither the cellular source nor the clinical significance of this residual viremia in patients on ART remains fully clear at present. Since residual plasma viruses generally do not evolve with time in the presence of effective ART, one prediction is that these viruses are persistently released at low levels from one or more stable but yet unknown HIV-1 reservoirs in the body during therapy. This review attempts to emphasize the source of residual viremia as another important reservoir (namely, "active reservoir") distinct from the well-known latent HIV-1 reservoir in the body, and why its elimination should be a priority in the effort for HIV-1 eradication.

• Authors: Gautam K Sahu
• Journal: AIDS research and human retroviruses (AIDS Res Hum Retroviruses) Vol. 31 Issue 1 Pg. 25-35 (Jan 2015) ISSN: 1931-8405 [Electronic] United States
• PMID: 25428885 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• Anti-HIV Agents

Topics

• Anti-HIV Agents (therapeutic use)
• Antiretroviral Therapy, Highly Active
• CD4-Positive T-Lymphocytes (virology)
• HIV Infections (drug therapy, virology)
• HIV-1 (growth & development)
• Humans
• Viral Load (drug effects)
• Viremia (drug therapy, virology)
• Virus Latency (drug effects)
• Virus Replication (drug effects)